- Home
- EVAX vs EKSO Comparison
EVAX vs EKSO Comparison
Compare EVAX & EKSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- EKSO
- Stock Information
- Founded
- EVAX 2008
- EKSO 2005
- Country
- EVAX Denmark
- EKSO United States
- Employees
- EVAX N/A
- EKSO N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- EKSO Medical/Dental Instruments
- Sector
- EVAX Health Care
- EKSO Health Care
- Exchange
- EVAX Nasdaq
- EKSO Nasdaq
- Market Cap
- EVAX 16.3M
- EKSO 13.6M
- IPO Year
- EVAX 2021
- EKSO N/A
- Fundamental
- Price
- EVAX $1.64
- EKSO $0.45
- Analyst Decision
- EVAX Strong Buy
- EKSO Strong Buy
- Analyst Count
- EVAX 2
- EKSO 2
- Target Price
- EVAX $10.00
- EKSO $2.50
- AVG Volume (30 Days)
- EVAX 64.1K
- EKSO 204.6K
- Earning Date
- EVAX 05-27-2025
- EKSO 05-05-2025
- Dividend Yield
- EVAX N/A
- EKSO N/A
- EPS Growth
- EVAX N/A
- EKSO N/A
- EPS
- EVAX N/A
- EKSO N/A
- Revenue
- EVAX $3,344,000.00
- EKSO $17,544,000.00
- Revenue This Year
- EVAX $102.45
- EKSO $0.20
- Revenue Next Year
- EVAX $100.30
- EKSO $42.29
- P/E Ratio
- EVAX N/A
- EKSO N/A
- Revenue Growth
- EVAX 4480.82
- EKSO N/A
- 52 Week Low
- EVAX $1.20
- EKSO $0.34
- 52 Week High
- EVAX $20.81
- EKSO $1.53
- Technical
- Relative Strength Index (RSI)
- EVAX 55.67
- EKSO 52.84
- Support Level
- EVAX $1.42
- EKSO $0.38
- Resistance Level
- EVAX $1.62
- EKSO $0.53
- Average True Range (ATR)
- EVAX 0.11
- EKSO 0.05
- MACD
- EVAX 0.03
- EKSO -0.00
- Stochastic Oscillator
- EVAX 62.86
- EKSO 48.68
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.